Figure 1.
Screening for T-cell responses towards minimal peptides derived from PD-L2. (A) Examples of ELISPOT results for PBMCs isolated from patients with malignant melanoma (AA and MM), in response to PD-L201 (PD-L24-12; LLLMLSLEL) and PD-L205 (PD-L216-25; QIAALFTVTV). (B) In-vitro IFN-γ ELISPOT results. PBMCs from 9 patients with malignant melanoma were stimulated once in vitro with each peptide. Then, the PBMCs were exposed to the peptides, and IFN-γ secretion was measured with ELISPOT. The response was calculated as the number of peptide-specific spots, minus the number of spots that reacted to an irrelevant peptide (HIV/HLA-A2; pol476-484; ILKEPVHGV), per5 × 105 PBMCs.